Soluble Vimentin Binding P-Selectin to Block Leukocyte Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are ineffective in reducing mortality and morbidity, as they fail to adequately address the pathologic inflammation caused by leukocyte recruitment to the lungs.
Innovation Solution
The use of soluble recombinant human vimentin (srhVim) to block leukocyte adhesion to platelets and endothelial cells by binding to P-selectin, thereby reducing inflammation and tissue injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for ALI and ARDS, then standard care is provided, but mortality and morbidity remain high due to ineffective suppression of pathologic inflammation
Solution Approach 1:
Vimentin acts as a soluble mediator that binds to P-selectin on platelets and endothelial cells, blocking the interaction between P-selectin and PSGL-1 on leukocytes. This intermediary approach prevents leukocyte adhesion and subsequent inflammation without requiring direct intervention in the inflammatory cascade, thereby reducing pathologic inflammation and improving mortality outcomes in ALI and ARDS
Solution Approach 2:
The patent extracts and utilizes the specific functional domain of vimentin (amino acids 96-407) that binds to P-selectin, separating this therapeutic function from the complete vimentin protein. This extracted peptide fragment maintains the anti-inflammatory activity while reducing complexity and potential side effects, enabling targeted suppression of P-selectin-mediated leukocyte recruitment
2Object-affected harmful factors
If leukocyte recruitment is blocked to reduce inflammation, then tissue injury is reduced, but normal immune function may be compromised
Solution Approach 1:
The vimentin-P-selectin blocking mechanism acts locally at the site of inflammation by specifically interfering with leukocyte-endothelium interactions in affected vascular beds. This localized intervention allows normal immune function in non-affected areas to continue while preventing tissue injury in inflamed regions, achieving selective protection without systemic immunosuppression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
srhVim effectively decreases leukocyte infiltration into the lungs, improves lung function, and reduces morbidity and mortality in ALI and ARDS by inhibiting leukocyte adhesion, providing a potential therapeutic approach for these conditions.
Implementation Method 1
The use of soluble recombinant human vimentin (srhVim) to block leukocyte adhesion to platelets and endothelial cells by binding to P-selectin
Data Source
AI summary
Embodiments of the disclosure include methods and compositions for treating or preventing acute inflammation using soluble vimentin. In specific embodiments, a vimentin derivative comprising the rod domain is utilized for treating or preventing any disease in which a decrease in leukocyte adhesion is therapeutic. In specific embodiments, a fragment of vimentin that comprises part or all of the rod domain is employed.